section name header

Pronunciation ⬇

me-TOLE-a-zone

Classifications ⬆ ⬇

Therapeutic Classification: antihypertensives, diuretics

Pharmacologic Classification: thiazide like diuretics

Indications ⬆ ⬇

REMS


Action ⬆ ⬇

  • Increases excretion of sodium and water by inhibiting sodium reabsorption in the distal tubule.
  • Promotes excretion of chloride, potassium, magnesium, and bicarbonate.
  • May produce arteriolar dilation.
Therapeutic effects:
  • Lowering of BP in hypertensive patients.
  • Diuresis with subsequent mobilization of edema. Effect may continue in renal impairment.

Pharmacokinetics ⬆ ⬇

Absorption: Absorption is variable.

Distribution: Extensively distributed to tissues.

Protein Binding: 95%.

Metabolism/Excretion: Excreted mainly unchanged by the kidneys.

Half-Life: 6–20 hr.

Time/Action Profile ⬆ ⬇

(diuretic effect‡)
ROUTEONSETPEAKDURATION
PO1 hr2 hr12–24 hr

‡Full antihypertensive effect may take days–wk.



Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

CV: chest pain, hypotension, palpitations

Derm: photosensitivity, rash

Endo: hyperglycemia

F and E: hypokalemia, dehydration, hypercalcemia, hypochloremic alkalosis, hypomagnesemia, hyponatremia, hypophosphatemia, hypovolemia

GI: anorexia, bloating, cramping, drug-induced hepatitis, nausea, pancreatitis, vomiting

Hemat: blood dyscrasias

Metab: hyperuricemia

MS: muscle cramps

Neuro: drowsiness, lethargy

Interactions ⬆ ⬇

Drug-drug:

Drug-Food:

Route/Dosage ⬆ ⬇

Availability ⬆ ⬇

(Generic available)

Assessment ⬆ ⬇

Lab Test Considerations:

Implementation ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

Canadian Brand Names ⬆

Zaroxolyn